Hangzhou Tianmushan Pharmaceutical Enterprise (600671.SH) plans to increase its capital by 50 million yuan to its subsidiary Huangshan Tianmu.

Hangzhou Tianmushan Pharmaceutical Enterprise (600671.SH) announced that, according to the company's strategic layout and future operational development needs, it will accelerate the implementation of capacity expansion and technological transformation projects at its wholly-owned subsidiary, Huangshan Tianmu, to promote the smooth realization of the company's strategic transformation. The company plans to increase its investment in Huangshan Tianmu by 50 million yuan with its own funds. After the capital increase, the registered capital of Huangshan Tianmu will increase from 30 million yuan to 80 million yuan, and Huangshan Tianmu will remain a wholly-owned subsidiary of the company.